Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal oxytocin for benzodiazepine withdrawal
2019-002280-10Phase 2Active
- Sponsor
- St. Olavs University Hospital
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in benzodiazepine withdrawal syndrome (BWS) comparing Intranasal oxytocin + diazepam taper with Placebo + diazepam taper (2 arms). Primary endpoint: Change in benzodiazepine withdrawal symptoms. Started Dec 2020; status: active.
02
Drugs
oxytocin
03
Conditions
benzodiazepine withdrawal syndrome (BWS)
Beyond the preview
Go deeper on 2019-002280-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002280-10.